MRK - Merck & Co., Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
59.185
+0.735 (+1.26%)
As of 2:38PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close58.450
Open58.450
Bid59.240 x 3200
Ask59.250 x 800
Day's Range58.430 - 59.490
52 Week Range52.830 - 66.410
Volume6,270,152
Avg. Volume11,424,806
Market Cap159.225B
Beta1.11
PE Ratio (TTM)68.03
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.92 (3.22%)
Ex-Dividend Date2018-03-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters3 hours ago

    Ebola patients slip out of Congo hospital as medics try to control outbreak

    T hree patients infected with the Ebola virus slipped out of an isolation ward at a hospital in the Congolese city of Mbandaka, health officials said, as medics raced to stop the deadly disease from spreading in the busy river port. Two patients left the hospital on Monday night with the help of family members, then headed to a church, the World Health Organization's spokesman in Congo, Eugene Kabambi, told Reuters.

  • Reuters3 hours ago

    Merck's cancer drug Keytruda notches another trial success

    Merck & Co said on Wednesday its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market. Keytruda, already approved for other types of cancer, is being studied in a late-stage trial as a first-line treatment, in combination with chemotherapy, for metastatic squamous non-small cell lung cancer (sNSCLC) patients. Merck said the combination therapy met its main trial goals when compared to patients who were on chemotherapy alone, according to an interim analysis.

  • Why the world needs more than one Ebola vaccine
    Reuters4 hours ago

    Why the world needs more than one Ebola vaccine

    LONDON (Reuters) - - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck (MRK.N) - seems bound to win. Immunisations with Merck's VSV EBOV experimental shot began in Congo this week - a big moment in a 40-year fight against a disease that until now could only be tackled by isolation and strict hygiene. Having this vaccine means the world is better placed now than it was in 2014-2016, when the haemorrhagic fever killed more than 11,300 people in history's worst Ebola outbreak in West Africa.

  • Reuters7 hours ago

    Three Ebola patients escape Congo quarantine, medics race to control outbreak

    T hree patients infected with the deadly Ebola virus escaped from a hospital holding them in quarantine in the Congo city of Mbandaka, an aid group said, as medics raced to stop the disease spreading in the teeming river port. Two of the patients got out on Monday but were found dead a day later, said Henri Gray, the head of the Medecins Sans Frontieres (MSF) mission in the city. The report came as the World Health Organization warned that the fight to stop Democratic Republic of Congo's ninth confirmed outbreak of the hemorrhagic fever had reached a critical point.

  • MarketWatch7 hours ago

    Merck’s experimental and unlicensed Ebola vaccine is being used in latest outbreak

    The World Health Organization has started to vaccinate thousands of people considered at high risk of contacting the infectious and often-deadly disease Ebola in the Democratic Republic of Congo. The WHO said Monday it is working with NGOs and community leaders to administer an experimental vaccine that was studied in a trial in Guinea in 2015, but has not yet been used to contain a major outbreak. Most are in a remote town, but there are four confirmed cases in Mbandaka, the provincial capital which has a population of more than 1 million people.

  • Reuters8 hours ago

    Three Ebola patients escape quarantine in Congo, two later die - MSF

    T wo of three Ebola patients who escaped quarantine in the Congo river port city of Mbandaka have died, the head of medical charity Medecins Sans Frontieres' mission in the city said on Wednesday. The ...

  • Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?
    Market Realistyesterday

    Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?

    Late last week, Johnson & Johnson (JNJ) announced that it was scrapping its mid-stage trial for the development of the treatment of Alzheimer’s disease, EARLY, which was in Phase 2b/3. The trial was testing the BACE inhibitor atabecestat. Johnson & Johnson is the latest in a series of companies, including Pfizer (PFE), Merck & Company (MRK), and Eli Lilly and Company (LLY), that have abandoned trials for their Alzheimer’s drug candidates.

  • The Wall Street Journal2 days ago

    [$$] Ebola Vaccination Begins in Democratic Republic of Congo

    Health officials in the Democratic Republic of Congo began administering an experimental Ebola vaccine, as the country battles to contain its ninth outbreak of the hemorrhagic fever. The first people to receive the vaccine on Monday were staff at a 20-bed Ebola treatment center set up by medical charity Doctors Without Borders in the northwestern city of Mbandaka, said Jessica Ilungu, a spokeswoman for Congo’s public-health ministry.

  • Factbox - From sterling crises to Brexit, the tests of Bank of England bosses
    Reuters2 days ago

    Factbox - From sterling crises to Brexit, the tests of Bank of England bosses

    British finance minister Philip Hammond is looking for a new governor of the Bank of England to replace Mark Carney when he leaves the central bank next year. The position is one of the most powerful in Britain with responsibilities for steering interest rates for the world's fifth-biggest economy and overseeing the City of London's vast financial services industry. Following is a summary of how some of the BoE's governors of the last 50 years have faced up to the challenges of the job.

  • Reuters2 days ago

    Congo begins giving experimental Ebola vaccine to medics

    C ongo began administering an experimental Ebola vaccine to medical staff in the northwestern city of Mbandaka on Monday to tackle an outbreak of the virus believed to have killed 26 people since early April. The World Health Organization (WHO) hailed the vaccinations as a "paradigm shift" in how to fight the disease which killed more than 11,300 people in a West African epidemic between 2013 and 2016. The WHO is sending over 7,540 doses of the vaccine to the central African country, 540 of which have been earmarked for Mbandaka, a city of about 1.5 million where four Ebola cases have been confirmed.

  • InvestorPlace2 days ago

    7 ‘Blue-Chip Stocks’ That Aren’t Blue Chips at All

    A lot of large-cap familiar names are still called “blue-chip stock” when they are nothing of the kind. If you can’t rid the term “blue-chip stock” from your lexicon, then it should at least apply to a whole new stream of companies. “Blue-chip stock” used to refer to companies that were constantly growing earnings in the high single-digits or more in terms of percentage, had a fortress balance sheet and were constantly innovating.

  • A Look into Roche Holding’s Performance in Q1 2018
    Market Realist2 days ago

    A Look into Roche Holding’s Performance in Q1 2018

    In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.

  • Reuters3 days ago

    Congo to begin Ebola vaccinations on Monday - health ministry

    Health workers in Democratic Republic of Congo will begin a vaccination campaign on Monday aimed at containing an outbreak of the deadly Ebola virus, a spokeswoman for the health ministry said on Sunday. ...

  • Eli Lilly’s Valuation on May 17
    Market Realist5 days ago

    Eli Lilly’s Valuation on May 17

    Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.

  • 3 Dow Stocks to Buy With Dividends Yielding More Than 3%
    Motley Fool5 days ago

    3 Dow Stocks to Buy With Dividends Yielding More Than 3%

    These well-known companies will deliver the dividend income you need.

  • Investopedia5 days ago

    Why J&J's Stock May Plunge 10%

    Johnson & Johnson ( JNJ) shares may drop by about 10% based on an analysis of the technical chart. Should shares of the stock fall an additional 10%, it would mean Johnson and Johnson would have dropped by nearly 25% from its intraday high of around $148 on January 22. The technical setup continues to be negative in the stock, and it appears shares could fall from roughly $124.25 to about $111.33, a drop of 10.4%.

  • InvestorPlace6 days ago

    Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks

    The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.

  • Taking Stock of Gilead Sciences’ Key Developments
    Market Realist6 days ago

    Taking Stock of Gilead Sciences’ Key Developments

    During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.

  • Roche Tecentriq Combo Achieves Longer Overall Survival Rate
    Zacks6 days ago

    Roche Tecentriq Combo Achieves Longer Overall Survival Rate

    Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

  • Novartis Gains Ground, Completes the AveXis Acquisition
    Market Realist6 days ago

    Novartis Gains Ground, Completes the AveXis Acquisition

    Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.

  • The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial
    Zacks6 days ago

    The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial

    The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial

  • Gilead Sciences’ Cash Flows, Valuations, and Price Performance
    Market Realist6 days ago

    Gilead Sciences’ Cash Flows, Valuations, and Price Performance

    Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.

  • Reuters7 days ago

    Roche immunotherapy combination increases lung cancer survival-study

    Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. The Phase III study involved 800 people with non-squamous non-small cell lung cancer (NSCLC) whose cancer had spread but who had not yet received chemotherapy.

  • Reuters7 days ago

    Merck's Keytruda boosts response in hard-to-treat lung cancer

    The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday. An early look at results of a 204-patient trial showed an overall response rate of 58.4 percent for newly-diagnosed patients given Keytruda plus carboplatin and paclitaxel or Celgene Corp's Abraxane. The interim results will be discussed in greater detail next month at the annual meeting of the American Society of Clinical Oncology (ASCO), where data from several Keytruda trials and other therapies that help the immune system fight cancer will be presented.